Biotech News
Related news
OTLKOutlook2026-05-28 20:00 EST
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
OTLKOutlook2026-09-11 11:00 EST
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
BLTEBelite Bio2026-04-27 12:00 EST
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
OKYOOKYO Pharma2026-07-21 13:00 EST
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
BLTEBelite Bio2026-07-15 12:00 EST
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
OCSOculis2026-07-02 08:00 EST
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
TARSTarsus Pharmaceuticals2026-09-01 20:30 EST
Tarsus to Participate in Upcoming Investor Conferences
SGHTSight Sciences2026-09-01 20:05 EST
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
IRIXIRIDEX2026-06-09 20:05 EST
Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
OCSOculis2026-06-08 19:25 EST
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
Outlook
Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...
Recent company news
OTLKOutlook2026-09-11 11:00 EST
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
OTLKOutlook2026-09-10 13:10 EST
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
OTLKOutlook2026-08-27 20:05 EST
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
OTLKOutlook2026-08-27 13:01 EST
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
OTLKOutlook2026-08-14 11:15 EST
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Stock data
- Close
- 0.68 USD
- Market cap
- 120.89M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States